Christian L. Andersen, PhD, is a Senior Scientist II in Nonclinical Development at Antares Therapeutics in Boston, where he is Toxicology Technical Lead for small-molecule programs from lead optimization through regulatory filing and early clinical trials. At Schrödinger, he led toxicology strategy for programs through IND filing and early clinical development, serving as sole GLP study monitor for three oncology INDs and primary author of a successful IND. Earlier, he was a GLP Study Director for developmental and reproductive toxicology studies at Charles River Laboratories. His work combines computational toxicology (QSAR, machine learning–based hazard prediction and in silico secondary pharmacology) with New Approach Methodologies and in vivo data to guide safety decisions. He earned his PhD in Toxicology from the University of Georgia. He lectures at Rutgers University, serves on the editorial board of the International Journal of Toxicology, and is a counselor for SOT’s Computational Toxicology Specialty Section.

Michael Annichine is the CEO of Magee-Womens Research Institute & Foundation (MWRIF), where he leads the development to sustain programs and research at UPMC Magee-Womens Hospital and Magee-Womens Research Institute, the largest research institute in the U.S. focused solely on women’s health and reproductive biology. The research institute, based in Pittsburgh and building collaborations around the world, is home to hundreds of world-class researchers who have devoted their careers to advancing the health of women. MWRI’s medical research spans a woman’s lifetime from nine months to 90+ years and focuses on improving women’s lives by learning more about the various conditions and diseases from which they suffer. Under Michael’s leadership since 2016, MWRIF has expanded its partnerships with industry, academia, and foundations and significantly grown its revenue base while capitalizing on the translational impact of its scientific investment. Michael is a seasoned professional with more than 20 years’ experience starting, developing, and leading local and national businesses across a variety of growth industries. Prior to his current position, Michael held the Chief Executive roles at C-leveled, FlyerCity Media, and CFS Home Loans, Inc. where his companies were twice named to the Inc. 1000 Fastest Growing Companies in America list. A Carnegie Mellon University alumnus and former Director of Investment Programs at the Pittsburgh Life Sciences Greenhouse, Michael has measurably impacted the Pittsburgh start-up community and built strong connections with business, private equity, and venture capital partners.

Yana Aznavour, MD, PhD, is the CEO and Founder of Endometrics, a company building a new category of precision diagnostics from at-home collected menstrual blood. Its first test addresses endometriosis, and the platform is expanding into gynecologic cancers. She is an ObGyn and minimally invasive gynecologic surgeon with more than a decade of experience across clinical care, translational research and product development, and an advocate for clinically meaningful testing that reaches the right patients at the right time. She received the Best Research Award from the American Association of Gynecologic Laparoscopists (AAGL) in 2020. In 2026, under her leadership, Endometrics won first prize in the NIH RADx Tech ACT ENDO Challenge and the Precision Medicine World Conference’s Most Promising Company competition.

Elnur Babayev, MD, MSc, is an Assistant Professor of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine and a board-certified reproductive endocrinologist and infertility specialist. He is an NIH Women’s Reproductive Health Research (WRHR) Scholar whose research focuses on two major areas: basic and translational research in ovarian aging and drug discovery for women’s health conditions. His laboratory investigates the molecular and cellular mechanisms underlying ovarian aging, with an emphasis on identifying novel biomarkers and therapeutic targets to improve reproductive longevity. His drug discovery efforts focus on developing novel therapeutics to address unmet needs in reproductive medicine and women's health. Dr. Babayev completed his medical training at Istanbul University, earned an MSc in Clinical Embryology from the University of Oxford, and completed postdoctoral training at Yale University, followed by residency and fellowship training at Northwestern University.

Amy Beckley graduated with her PhD in Pharmacology from University of Colorado. She has studied everything from breast cancer progression to vaccine development. She began to focus on hormonal health after her personal battle with infertility and miscarriage. Amy founded Proov in 2016, with the mission to track and analyze hormones to finally understand hormones and how to treat diseases of the menstrual cycle with more precision and speed.

Vanessa Belozeroff brings over 30 years of experience in her role as the leader of Portfolio and Program Management at Organon, where she leads the planning, integration, operations and governance of a portfolio of established brands, innovative therapies, and new portfolio building opportunities to address unmet medical needs for women. Before joining Organon, Vanessa was at Amgen where during her 18-year tenure, was the head of program management and business operations where she helped lead the establishment of Amgen’s biosimilar business and guide the strategy to deliver a sustainable pipeline and >$2B in revenue. She was also the head of the bone and hematology, oncology portfolio where she led the strategic advancement and commercialization for >30 products, launched three products which delivered >$13B revenue and managed strategic alliances with global businesses partners. In addition, she drove product strategies in Amgen's nephrology and blood franchise and led R&D M&A assessments and integration. Before Amgen, Vanessa held roles in program leadership, clinical operations, medical research, manufacturing, and research science at companies including Sanofi, Abbott, Johnson & Johnson/McNeil. Vanessa holds an MBA from Eastern University and a BS in Bacteriology from the University of Idaho.

Dr. Bharadwaj is Executive Director, Drug Discovery Analytics at Revolution Medicines, where she is building and leading a new AI/ML team to advance the company’s RAS(ON) inhibitor platform, including its work on daraxonrasib, zoldonrasib, and elironrasib. In this role, she is embedding AI across target identification, molecule design, and translational research to accelerate discovery against RAS-driven cancers — one of oncology’s most historically challenging targets. She brings prior experience leading enterprise AI adoption at Novartis, Sanofi, and Biogen, along with a background at MIT Lincoln Laboratory. She also founded Prevara, a startup supporting preconception health, and mentors emerging talent through Women in AI and Nucleate.

Dr. Bischoff is an experienced professional with over 25 years of expertise in developing non-invasive clinical assays for various women’s health conditions such as endometriosis, IVF/ART, prenatal testing, and oncology. She has managed several research projects, published over 300 articles, and mentored executives and medical students alike. Dr. Bischoff has been recognized with numerous awards for her research, including the discovery of germline mutations in the p53 tumor suppressor gene. As CEO and CSO of FreMon Scientific, she successfully led the company’s first commercial product, ZipThaw202, through FDA clearance and transitioned it to the commercial stage during the COVID-19 pandemic. Dr. Bischoff has a Ph.D. in Cancer Biology and has received postdoctoral training from M.D. Anderson Cancer Center and Baylor College of Medicine.

As President of the Catalytic Impact Foundation since 2018, Rachel has helped to guide the growth of the organization to become a philanthropic leader in deploying catalytic capital to accelerate innovation in underfunded areas of healthcare, where there are significant unmet medical needs. These areas of focus include women’s health, children’s health, and brain/mental health. She has extensive experience and expertise analyzing, evaluating, and investing in early- and mid-stage companies in the life sciences and healthcare industry, and has served as a team leader managing the investment analysis and processes at the Catalytic Impact Foundation. Previously, she served as Co-Founder and Editor-in-Chief of Asthma Magazine, a patient education publication for asthma and allergy. The magazine was used by the NHLBI in its national children’s asthma (CAMP) study; by Merck to launch its first-in-class asthma drug, Singulair; and by the American Lung Association, the American Academy of Asthma, Allergy and Immunology, the National Association of School Nurses, and private practitioners throughout the country, to educate their patients about the condition. Subsequently, she guided the company through its acquisition by Elsevier Health Sciences, a leading publisher of medical journals, where she continued as Editor-in-Chief.

Dr. Mia Chorney, DNP, FNP-BC, MSCP, is Co-Founder and Chief Medical Officer of The Pause Technologies, Inc., parent company of the Harmoni® app and Amsara Health. She leads the clinical vision behind Harmoni®, a voice-enabled AI companion for perimenopause and menopause. Harmoni® acts as an intelligent agent: it reads a woman's wearable data, alongside the symptoms and details she shares and the sentiment in her own words, then brings it all together into one picture of her health. From there, it offers personalized, precision recommendations and guided meditations, and connects her to Amsara Health's concierge telehealth clinic, so she can tell her story once and everyone who cares for her knows it. With nearly four decades, from critical care and the operating room to women's cardiology, genetics and menopause care, Dr. Chorney works where precision medicine, wearables and AI meet. She is a WHOOP Founding Clinician Ambassador and a member of the American Heart Association Board of Directors in Phoenix. She was named 2025 Female Founder of the Year by the Inno Fire Awards Arizona and a 2026 Top 100 Trailblazer in Menopause, and recently spoke at TEDxBoston.

Trish Costello is CEO and Founder of Portfolia and Managing Director of Portfolia Funds. Portfolia activates the wealth of women, with nearly 2,000 women limited partners in its venture capital funds. Portfolia’s 14 VC funds focus on industries that over-index for women, including Active Aging and Longevity, FemTech, Food/AgTech, Green & Sustainability, and Rising America (diversity). Portfolia created the first venture capital fund with a sole focus on women’s health in 2018, and the first led by five women of color partners in 2019. Portfolia is the most active VC firm in the US investing in women’s health and in health conditions that impact women differently. Portfolia has made over 150 investments, including unicorns Everly Health, GrubMarket, and Maven Clinic; and noted consumer products companies Madison Reed, Canela Media and Apollo Neuro. Trish is internationally recognized for her pioneering work in preparing venture capital investment partners through the prestigious Kauffman Fellows Program, which she created and spun out from the Kauffman Foundation and continues as CEO Emeritus. Trish was Founding President of CVE Capital Corp, the holding company of a $1.7 billion venture capital Fund of Funds founded to endow the Kauffman program. Costello was on the start-up team of the Kauffman Foundation’s entrepreneurship center, where she played a leading role nationally in increasing equity investments in women’s businesses and in funding initiatives supporting high-growth women entrepreneurs, as well as equity programs for all high-potential entrepreneurs. Trish led the National Science Foundation SBIR Sub-Committee on Commercialization and was the Director of the Arthur M. Blank Center of Entrepreneurship at Babson College. She led and exited venture-backed companies in the pediatric market earlier in her career. Trish’s numerous accolades include INSIDER’s Seed 30: The Best Women Early-Stage Investors of 2023, Springboard Enterprises and the New York Stock Exchange’s inaugural Investor of the Year in 2022, Entrepreneur Magazine inaugural 100 Most Innovative Women Entrepreneurs in the World in 2020. Portfolia won the 2019 Golden Stevie Award for the Year’s Most Innovative Company Run by Women as well as Fast Company's one of the 10 Most Innovative Finance Companies in the World in 2020, along with unicorns Brex and Carta.

Jenny Duan is the Co-Founder and CEO of Clair Health, the women’s health intelligence platform with a custom-built female world biology model grounded in research and data from its innovative wearable, Clair, the world's first noninvasive continuous hormone monitor. Clair’s wrist-worn wearable uses 10 sensors and more than 130 biomarkers to model hormonal patterns and translate them into personalized insights across sleep, energy, mood, exercise, recovery and long-term health.

Marlena Schoenberg Fejzo is a women’s health scientist. She has published peer-reviewed scientific articles on many diseases of women including ovarian cancer, breast cancer, multiple sclerosis, and discovered the first genes for uterine fibroids, nausea and vomiting of pregnancy, and hyperemesis gravidarum (HG). In 2018, Fejzo, in collaboration with personal genetics company 23andMe, Inc published the first link between the placenta, appetite, and vomiting hormone GDF15. In 2022, she published the first mutation in GDF15 associated with HG, solidifying the role of GDF15 as a predisposing factor for HG. In December 2023, Fejzo et al. published a study that identified the mechanism involved in nausea and vomiting of pregnancy and HG. The study identified ways to potentially prevent and treat both nausea and vomiting in pregnancy (common misnomer "morning sickness") and HG. Fejzo is an Assistant Professor at the University of Southern California, Keck School of Medicine in the Center for Genetic Epidemiology, Chief Scientific Officer of Harmonia Healthcare, Research Director and Board Member of the Hyperemesis Education and Research (HER) Foundation, Board Member of the Foundation for Women’s Health, and an advisor for NGMBio. Fejzo made the top 10 list of 2023's Fiercest Women in Life Sciences, and in 2024 was a Time Woman of the Year and Time 100 Health Honoree, received the National Organization of Women Victoria Mastrobuono Award in Women’s Health, Forbes 50 Over 50 award in Innovation, a finalist for Falling Walls Breakthrough of the Year, and the inaugural BII and Science Translational Medicine Innovation in Women's Health prize winner.

Angelika Fretzen, PhD, MBA, is passionate about uniting and stewarding powerful teams as they work to solve the most pressing problems facing our society in healthcare and sustainability. Throughout her career, it became evident to Angelika that the strength and health of women was integral to their own perspective on life, to their families, and to the societal ecosystem they participated in. Her deep commitment to bridging the acute healthcare and equity gap for women that we still face is evident in her championing the development of programs and technologies to address these gender-based issues. At the Wyss, she initiated the Wyss 99s that aims to encourage, develop, and provide resources to female leaders, entrepreneurs, and scientists. Through her passion of working towards health equity, Angelika was the impetus for the formation of the Women’s Health Catalyst with a vision of developing entirely innovative approaches to studying female biology and creating technologies to define healthy and disease responses that change dynamically over time much like a woman’s own physiology. In 2024, she received the prestigious Joseph B. Martin Dean’s Leadership Award for the Advancement of Women’s Careers at Harvard Medical School/Harvard School of Dental Medicine. Before coming to the Wyss, Angelika spent two decades in entrepreneurial pharmaceutical companies where she developed a deep commitment to improving healthcare for women and families. At Ironwood Pharmaceuticals, she spearheaded the discovery, development, and commercialization of LinzessTM, a first-in-class medication for Irritable Bowel Syndrome, a symptomatic disease that can be debilitating to many women in the most productive years of their life. Prior to the development of this therapeutic, effective treatment options were nonexistent until LinzessTM became available to physicians. At Catabasis Pharmaceuticals (now Astria TX), Angelika collaborated closely with the internal team, clinicians, advocacy groups, and families to bring Edasalonexent into Phase 3 clinical trials for the treatment of Duchenne Muscular Dystrophy, a rare genetic neuromuscular disease that affects young boys and their families. For 12 years, she also served on the Board of Bridgewell, a social and human service organization, where she facilitated programs for the homeless, individuals with disabilities, young adults with autism, and young mothers with a history of substance abuse. Angelika Fretzen is a chemist by training, completing her undergraduate studies in Germany and her PhD in Switzerland. She came to the United States for her postdoctoral research at Harvard University, before joining the early biotechnology community in Kendall Square in 2000. She holds an MBA from Suffolk University and is deeply committed to both the personal and career development of all scientists and employees around her. She was named one of Mass High Tech’s 2013 Women to Watch.

Maria Gonzalez Manso is CEO and co-founder of Tucuvi, building Clinical Voice AI to help bridge the gap between what patients clinically need and what healthcare teams have the capacity to deliver. Trained in Biomedical Engineering, she has spent the past several years working with health systems across Europe and the US, with Tucuvi now deployed across 80+ health systems. She is excited to share lessons from real world deployments on closing the trust gap in AI-driven remote monitoring, from the clinical evidence and governance care teams require to keeping human judgment at the center of chronic disease management.

Dr. Felicia Gray is a biomedical scientist working in small-molecule drug discovery at Schrödinger. Her work spans target ideation, biological rationale, and therapeutic concept evaluation, testing emerging ideas against data and unmet patient needs. Dr. Gray has served as biology lead on small-molecule programs across oncology, neuroscience, inflammation, and women’s health, contributing to two oncology INDs and building funding support and key research collaborations in non-hormonal contraception.

With more than 20 years of international experience in healthcare, Ikram Guerd has built a distinguished career at the intersection of marketing, innovation and leadership. Her journey spans global corporations, such as Procter & Gamble and Danaher Corporation, as well as entrepreneurial ventures in both Europe and the United States. Throughout, she has demonstrated a consistent ability to drive growth, manage product lifecycles and craft business strategies that not only deliver results but also shape organizational culture. Today, Guerd serves as chief marketing officer and general manager U.S. at Aspivix Corporation, where she is redefining women’s health by spearheading strategies to raise awareness around innovative solutions that reduce pain in gynecological care. Her leadership has positioned Aspivix as a disruptive force in a field long overlooked in terms of research, innovation and funding. Over the past two years, her accomplishments have been transformative. She established Aspivix’s U.S. C-Corporation in California, executed a groundbreaking growth marketing campaign that achieved more than 3.3 million views on TikTok and initiated the first U.S. clinical study for Carevix, an innovation designed to reduce pain during transcervical procedures. Her work has garnered widespread recognition, with international features in The New York Times, NBC News, CBS Mornings, Forbes, Women’s Health Magazine and FemTech Insider. Beyond her corporate achievements, Guerd is committed to mentorship and advocacy. She serves as a role model and board member for Inspiring Girls USA, helping to challenge stereotypes for young women, and previously held a communications board role with Women in Healthcare.

Anoushka Gungadin is an experienced CEO, Board Director, and cross-border executive, with a career spanning across four continents. Anoushka is the Managing Director and Chief Executive Officer of HeraMED, an ASX-listed femtech company focused on redefining maternity and pregnancy. She is a council member of Deakin University. She is the Australian lead for TiE Women, a global mentoring and investment platform for female entrepreneurs. She is a speaker and author on inclusive leadership and cultural intelligence. Her previous experience includes founding CEO of the Australia India Chamber of Commerce set up to drive bilateral economic relationships. She headed up finance and client accounts for Gide, the International French law firm for 10 years in Beijing. She has consulted and worked with brands including Mondelez, L’Oréal, Bank of Indonesia, Reliance, Rhipe-Crayon and more. A trained economist, she holds an MBA and is a certified professional coach.

Nada Hanafi is a thought leader within the Life Sciences and MedTech industry with over 22 years of experience across the public and private sectors. She is the Founder of MedTech Strategy Advisors, LLC where she advises life-science companies on regulatory strategy, product development, and clinical research to accomplish regulatory, compliance, and business goals. Nada spent over 12 years working for the FDA, serving in increasing roles of responsibility and ultimately as a Senior Science Health Advisor in the Center for Devices and Radiological Health (CDRH), where she led cross-Center and Agency programs for the advancement of FDA's mission to promote and protect public health, including as Co-Founder of the Health of Women (HoW) program, the Network of Experts program and the Patient Preference Initiative. She served as CDRH Liaison and Subject Matter Expert to FDA’s Office of Women’s Health (OWH) and the Office of Minority Health (OMH). She collaborated with the Center for Tobacco (CTP) and the National Institutes of Health (NIH) where she served as Senior Management Advisor to the Director at the Office of Research on Women’s Health (ORWH), to improve regulatory efficiency and to strengthen data collection. Nada’s drive and passion to address health inequities with a focus on women and minorities led her to Co-Found MedTech Color, a non-profit focused on advancing the representation of people of color within MedTech. Nada also serves on the Steering Committee and as Co-Chair on the (1) Regulatory and Science Policy subcommittee, and (2) Discovery & Development Accelerator committee for the Innovation Equity Forum (IEF) led by Gates Foundation, as well as on several Steering Committees for organizations such as the Reagan-Udall Foundation and Milken Institute, respectively. Nada holds an MSc in Biomaterials and a BEng in Biomedical Materials Science & Engineering from Queen Mary College, University of London. She earned her MPH from Johns Hopkins Bloomberg School of Public Health. Nada is a Certified Quality Improvement Associate (CQIA) and a Certified Quality Auditor (CQA) from the American Society for Quality (ASQ).

Colby Holtshouse is the CEO of May Health, a medtech startup addressing polycystic ovary syndrome (PCOS). Previously, Colby served as the Global Medtech Commercial Lead at Organon LLC. She joined Organon via the acquisition of Alydia Health, where she was the COO, Interim CEO, and Vice President Marketing. Colby was previously Vice President Marketing at Pelvalon, and held roles at AccessClosure, Medtronic, and Guidant. Colby has a BA from Stanford University and an MBA from Northwestern’s Kellogg School of Management.

Dr. Kathleen Jordan is one of the founders and Chief Medical Officer at Midi Health. At Midi, she leads a team of hundreds of clinicians serving women in all 50 states on their virtual telehealth platform that serves women in midlife. She is a menopause-certified provider and trained internist. Her background: Always a proponent of digital health and solving access issues, she has worked to leverage innovative technology into patient care. After running her practice, she became a Chief Medical Officer at St. Francis Hospital and, most recently, a leader in women’s healthcare startups, and joined the founding team at Midi Health in 2021 and has led the growth of services to become the leading menopause care solution and one of the largest national telehealth providers of women's care, serving tens of thousands of women every week. Her career has been highlighted by establishing telehealth services at the Hospital site, attaining Health Equity Leadership Certification for the Hospital and its programs, and establishing a new trans health program in San Francisco for which she was awarded the Leadership in Innovation award. She joined the founding team at MidiHealth to help advance the access to expert care. Her expertise has been featured in multiple news outlets, publications, and podcasts. She is a graduate of the UCLA School of Medicine and Stanford University. Midi Health has experienced fantastic growth and recognition since its inception in 2021.

Petrina Kamya, PhD, is the Head of AI Platforms and President of Insilico Medicine, Canada an end-to-end artificial intelligence-driven drug discovery company. Before joining Insilico, Dr. Kamya spent eight years in various roles at Chemical Computing Group that involved scientific and business-related aspects of preclinical drug discovery. In addition to establishing the corporate strategy for the sales and business development of molecular modeling software for academia, she also played an active role as an application scientist working on real-world discovery projects and finally in a senior role in strategy and business development for pharma and biotech companies. Following her time at CCG, Petrina moved to Certara as a Market Access Manager, where she learned first-hand the challenges of getting drugs to market. Petrina has been with Insilico Medicine since August 2020. She holds a PhD in Chemistry (specializing in computational chemistry) from Concordia University.

Elise is a Managing Director at the American Heart Association's Go Red for Women Venture Fund—a Series A/B fund that invests in conditions that affect women's heart and brain health. Prior to joining the Heart Association, she spent 4 years at Human Ventures—a pre-seed and seed-stage venture fund in NYC. There, she worked in the venture studio and on the investment team. Elise started her career at Oxeon. She spent five years working across its healthcare venture studio and executive search divisions. Elise's first career was a professional dancer. She performed for the renowned modern dance company Jennifer Muller/The Works. She graduated magna cum laude from Barnard College, Columbia University, and is actively involved in the organization for women in VC, All Raise. The thread throughout her career has been empowering women, whether it be through supporting their VC careers, getting executives on boards, investing in their health, or investing in the care economy.

Dr. Kommagani is the Roger D. Rossen Endowed Professor of Reproductive Pathology at Baylor College of Medicine and a leader in microbiome-driven innovations for women's health. His groundbreaking research established a causal role for the gut microbiome in endometriosis and led to the discovery of a stool-based metabolic signature with potential as a noninvasive diagnostic test. His laboratory also identified microbiome-derived therapeutic candidates that are advancing new treatment strategies for endometriosis. These discoveries generated multiple patents and launched startup companies focused on diagnostics and therapeutics. Through a combination of scientific discovery, translational research, and commercialization, Dr. Kommagani is advancing microbiome-based solutions aimed at improving the diagnosis and treatment of endometriosis.

Mitzi Krockover, MD is Founder and CEO of Woman Centered, LLC, a women's health consultancy and producer of the "Beyond the Paper Gown" podcast. She serves as a managing director at Golden Seeds, which invests in early-stage women-led companies, where she co-chairs the Health Sector Group and co-founded the Arizona chapter. Dr. Krockover co-founded FemtechAZ and serves on advisory bodies including the Women's Health Innovation Council of Springboard, the Black Women's Health Imperative, the Gates Foundation’s Innovation Equity Forum and Women’s Health Advocates. She is also a Professor of Practice at ASU College of Health Solutions, developing coursework on women’s health innovation. Her previous positions include Founding Medical Director of the Iris Cantor-UCLA Women's Health Center and Vice President of Women's Health at Humana Inc.

Seema Kumar joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.

La Keisha Landrum Pierre is a forward-thinking venture capitalist, strategic operator, and three-time founder reshaping early-stage investing. As Co-Founder and Managing Partner of Emmeline Ventures, she leads a top-performing, operator-led fund deploying capital into high-growth, tech-enabled startups. Her investment thesis anchors a robust portfolio of over 35 market-leading companies transforming women’s health, wealth, and sustainability—building vital modern infrastructure while driving exceptional returns. Her investment playbook is backed by over 13 years of hyper-scaling operational experience. As the former CEO and COO of Sahara Reporters Media Group, she scaled the platform's audience from 2 million to 50 million monthly users and secured millions in institutional capital. Her deep background in venture validation includes building two startups through the Harvard Innovation Lab—yielding a successful digital health exit—and directing advanced technology research at Harvard Law School’s Berkman Klein Center. This track record has earned her global industry recognition. La Keisha was recently named one of PEI’s 50 Women of Influence in Private Markets and featured by Venture Capital Journal for her work in capital-efficient fund design. An expert speaker, she recently took the stage at Carta’s Innovators Summit to outline next-generation fund architectures and capital allocation strategies. Her leadership across private markets has commanded prestigious accolades. The Aspen Institute selected her as a 2025 Aspen Ideas Health Fellow, complementing consecutive honors including the Los Angeles Business Journal Women’s Leadership Awards and the LA Times Studios Inspirational Women Forum & Leadership Awards. La Keisha seamlessly pairs enterprise scalability with institutional execution, unlocking major, undervalued market opportunities.

Jennifer Law (Maternal Health Venture Leader) leads new business incubation in women’s and maternal health for Connected Care at Philips. Her work has included at-home perinatal monitoring, high-risk pregnancy management, and women’s cardiovascular health. She also engages in maternal health policy and government affairs and serves on advisory bodies, including the Massachusetts Maternal Health Task Force. Prior to Philips, Jennifer worked as an innovation and strategy consultant.

Michael N. Liebman, PhD (theoretical chemistry and protein crystallography) is Managing Director of IPQ Analytics, LLC and CSO of United Cancer Centers after serving as Executive Director of the Chan Soon-Shiong Institute for Molecular Medicine. He is Adjunct Professor of Pharmacology and Physiology, Drexel College of Medicine and Adjunct Professor of Drug Discovery, Wenzhou Medical University and Fudan University. He serves on the Advisory Board for the Center of Biomedical and Health Research, University of Massachusetts (Lowell). Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center. He served as Global Head of Computational Genomics, Roche. He serves on the Board of the Nathaniel Adamczyk Foundation in Pediatric ARDS. Michael chairs Translational Medicine for the PhRMA Foundation and serves on the IUPAC Division on Human Health. His research focuses on computational models of disease that stress complexities of real-world patients and real-world clinical practice utilizing systems-based approaches for representation and analysis for pharma and healthcare. Current application areas include: multiple sclerosis, heart failure, and a focus on women’s health: triple negative breast cancer, hypertension and hypertensive disorders of pregnancy, infant-maternal morbidity and mortality, perimenopause-menopause transition with an emphasis on underserved populations and health disparities.

Kelsey Mayo, PhD, is the co-founder and CEO of Armor Medical Inc., a biomedical device company pioneering wearables that safeguard maternal health. A multidisciplinary scientist and empathetic leader with 20 years of experience in precision medicine, Dr. Mayo builds teams that bridge science, engineering, and product development. She previously helped build and launch one of the world’s largest and most diverse biomedical research databases through the NIH’s All of Us Research Program, overseeing five national product launches. An award-winning innovator, she has been recognized as a Change Cultivator 40 Under 40 Global Change Leader and was the 2025 MedTech Innovator Grand Prize Winner. At Armor Medical, she combines her technical and leadership experience with her lived experience as a mother and hemorrhage survivor to develop a real-time early warning system for maternal hemorrhage. She is passionate about turning overlooked needs in women’s health into scalable solutions that improve care for women and families.

Margaret Melville is the CEO and Co-Founder of Lasa Health, a health technology company leveraging artificial intelligence to support the early diagnosis and management of chronic pelvic pain. Her work addresses the persistent 6–12 year diagnostic delay for conditions such as endometriosis by integrating machine learning into clinical decision support tools used at the point of care. Lasa Health’s platform has been validated in collaboration with Mayo Clinic and supported by the NSF, ARPA-H, and the Colorado Office of Economic Development. She holds an MBA from INSEAD and has experience across global health, medical devices, and impact investing. She lives in Boulder, Colorado, where she enjoys raising goats, mushroom foraging, and speed puzzling.

Dr. Jayne Morgan is an accomplished Cardiologist and Vice President of Medical Affairs at Hello Heart, with a strong focus on Women’s Health. As a recognized medical expert, she also provides frequent on-air medical analysis for CNN. With extensive experience in cardiovascular research, she is a recognized advocate for health equity, particularly in increasing women and minority participation and representation in clinical trials. Dr. Morgan has held leadership positions at Piedmont HealthCare, where she led community health education efforts and the Covid Task Force. As the sole Cardiology advisor on the research team at AbbVie (formerly Abbott Labs), Dr. Morgan made a groundbreaking contribution to the development of the Mitraclip, a minimally invasive device for treating mitral valve regurgitation. Moreover, she has published multiple studies in both Cardiology and Covid-19. Dr. Morgan is also well known for her award winning social media series, The Stairwell Chronicles, which provides accessible medical information in an easy to understand format. Further, Dr. Morgan has been named to the Top 500 Most Powerful Leaders in Atlanta for 2 years in a row, and has been acknowledged with numerous other accolades, including the NAACP Award, the National Women's Empowerment Award, the GA Bio Award, the American Heart Association Metro Atlanta Award, Medical Association of GA Humanitarian Award, the Atlanta Business Chronicle, just to name a few. She holds an Adjunct Associate Medicine Professorship at The Morehouse School of Medicine, and serves on various advisory boards and Steering Committees, including GeoVax and Novartis. Her pioneering work in cardiovascular research, clinical trials, and women's health has made her a respected voice in the medical community. Outside of her professional work, Dr. Morgan is also a certified pilates instructor, promoting overall health and wellness in and out of the clinic.

Mallika Mundkur is a physician-scientist who works at the intersection of medicine, public health, policy and innovation. A practicing, board-certified internal medicine physician, she has been a Clinical Assistant Professor at the George Washington University since 2015, where she teaches medical students. She spent nine years at the U.S. Food and Drug Administration. Most recently, as Deputy Chief Medical Officer in the Office of the Commissioner, she oversaw strategy and operations for five suboffices spanning pandemic preparedness, emerging threats, supply chain, orphan drugs, combination products, clinical policy, clinical trials, ethics and pediatric therapeutics. She served as a key liaison between senior FDA leadership, staff across the Agency and external stakeholders, and helped shape the Agency's modernization of regulatory science. Mallika earned her MD at the University of Massachusetts Medical School and trained in internal medicine at the University of Alabama at Birmingham, where she went on to serve as Chief Medical Resident and Instructor of Medicine. She completed a clinical informatics fellowship at the National Library of Medicine at the National Institutes of Health, and a general medicine fellowship in pharmacoepidemiology at Brigham and Women's Hospital and Harvard Medical School, where she earned her MPH. She has practiced as an attending physician at the George Washington University and at Brigham and Women's Hospital. She is a graduate of Harvard College. She now serves as an advisor and consultant to executive leadership teams across the healthcare industry.

Raquel Mura is a distinguished global regulatory strategist and R&D transformation expert, celebrated for her ability to develop high-performing cross-functional teams. She is an advocate for the role of technology and AI in enhacing decision making, innovation, and the human experience, having spearheaded digital transformation initiatives, including advanced analytics and automation of processes. Mura has successfully optimized global R&D operations, transformed operating models, and has crafted regulatory strategies to drive innovation and pipeline growth. Her career includes leadership roles at Sanofi, Pfizer, Novartis, and Bristol-Myers, having lived and worked in North America, Europe and South America. A PharmD, JD and MBA, she has earned accolades such as the TOPRA Inspiration Award, HBA Luminary and recognition as one of America’s Most Inspirational Women in Leadership. A committed advocate for equity, she led and contributed to various initiatives, including the HBA's Gender Equity Think Tank.

Candace Nagaraja is a Managing Director and Partner with LEK Consulting, where she leads the US Women's Health practice across medical device, provider services, diagnostics, and consumer health. Outside of LEK, Candace sits on the Springboard Women's Health Council acting as a mentor for innovative women's health startups. Candace received her AB in Economics from the University of Chicago College and her MBA from the University of Chicago Booth.

Gabriele Niederauer, PhD, FAIMBE, “Gabi” is CEO and Co-Founder of Freyya, Inc., a medical device company developing a tampon-like wearable that provides real-time biometric data to enhance pelvic floor physical therapy and improve patient outcomes. Freyya, Inc. has invented and designed an intra-vaginal device to aid in training and monitoring the pelvic floor. The company's novel device simultaneously measures pelvic floor force and intra-abdominal pressure, which are then transmitted wirelessly to a smart device for real-time feedback. We have completed a 25-participant clinical study demonstrating comfort, secure fit, and repeatable measurements, positioning Freyya for FDA clearance early next year. This product will empower women of all ages to monitor the condition of their pelvic floor muscles and provide real-time feedback to their physical therapists or healthcare provider. Gabi has over 30 years of past experience in product development and commercialization of four separate medical device companies: Bluegrass Vascular Technologies, ENTrigue Surgical, C2M Medical and OsteoBiologics. Serving in key senior management, CEO and Board positions, her leadership expertise was critical to the successful development and acquisitions of those companies.

As CEO of Medicines360, Dr. Andrea Olariu leads the organization in its mission to expand access to health innovations for all women from day one. She established the organization’s groundbreaking 360 Innovation Hub to identify and address critical health gaps for women, in order to bring needed innovations to women everywhere. Since joining Medicines360 in 2010, Dr. Olariu has held several key roles within the organization. She oversaw the development program for Medicines360’s first product, a hormonal intrauterine device (IUD), that included the largest and most diverse U.S. Phase 3 clinical study ever on an IUD. This work catalyzed broader access to the IUD for all women. Following FDA approval of the IUD in 2015, Dr. Olariu led the strategy to further extend the IUD’s duration of use and to make it available in several low- and middle-income countries. Dr. Olariu is a medical doctor specializing in dermatology and venerology with a PhD in Immunology, who started her career in academia. She was previously Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and Senior Lecturer of Immunology at the Victor Babes University of Medicine and Pharmacy in Timisoara, Romania. Prior to joining Medicines360, Dr. Olariu developed and implemented clinical and regulatory strategies for medical devices that received approval in the United States, Canada, and European Union. Her commitment to women’s health is shaped by her upbringing in Romania when human rights and access to health care, particularly for women, was very limited. Dr. Olariu has authored more than 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.

Michele M. Oshman is Chief Patient Advocate, Senior Vice President, Alliance Development at the Biotechnology Innovation Organization (BIO). BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. In her role, she leads an incredibly strong patient advocacy team, where she oversees BIO’s engagement with patient advocacy and other key stakeholder communities, drives support for members’ patient engagement and patient advocacy work, and ensures BIO’s policies reflect patient perspectives. Ms. Oshman joined BIO in January 2020 after a successful 18-year career at Eli Lilly and Company, where she led federal alliance development outreach. She served in multiple clinical development, patient advocacy and corporate leadership roles, earning a Six Sigma Black Belt, and leading multiple transformational efforts across the company. Ms. Oshman serves on the Board of Directors for the National Health Council (NHC). Created by and for patient organizations more than 100 years ago, NHC brings together over 160 national health-related organizations and businesses, including 100 patient advocacy groups. NHC drives drive patient-centered health policy and promotes access to affordable, high-value, and equitable health care. She is serving her second term on the Board of the American Brain Coalition, a non-profit organization comprised of professional and academic organizations focused on brain health. In 2023, she was elected to Health On Wednesday, a women’s organization whose membership is limited to 45 executive health policy leaders. Ms. Oshman also serves on the prestigious Committee on Nominations and Leadership Development for the American Association for the Advancement of Science (AAAS). An active member of the Japan America Society of Washington DC, Ms. Oshman graduated from American University with a dual degree in Political Science and Communications. She has two wonderful children, a loving husband of over 26 years, an oversized Akita, and a very small house.

Valerie B. Palmieri is an accomplished healthcare and biotech executive, board leader, and Founder and CEO of Momentum Consulting, LLC. She has held executive and board positions across public and private companies, overseeing organizations with more than 1,000 employees. Through Momentum Consulting, Valerie advises diagnostic companies in oncology, women’s health, and neurodegenerative disease on reimbursement, market access, laboratory operations, commercialization, and mergers and acquisitions. Her expertise includes Medicare coverage and coding pathways, including MolDX, Local Coverage Determinations (LCDs), and Advanced Diagnostic Laboratory Test (ADLT) designation. She is also a frequent speaker on FDA regulation of laboratory-developed tests. Valerie champions women’s health and FemTech as an advisor, board member, and healthcare policy advocate. At Women’s Health Advocates, she co-chairs the Reimbursement and Menopause Committees, supporting legislative initiatives to advance menopause care and midlife women’s health. She has also engaged with CMS and FDA on emerging diagnostic regulatory pathways. Her previous leadership roles include Executive Chair, CEO/President, and COO of Aspira Women’s Health; CEO/President of Diagnocure; and Senior Vice President of Operations at Laboratory Corporation of America and DIANON Systems. Valerie holds a BS in Medical Technology, with honors, from Western Connecticut State University, a Mini MBA from Elon University, and executive education certificates from Columbia Business School, Stanford Directors College, and the Wharton School.

Jenica Patterson, Ph.D., is Senior Director of the Women’s Health Network at the Milken Institute, where she leads a global initiative to accelerate innovation, investment, and cross-sector collaboration in women’s health. She works at the intersection of science, commercialization, and capital, mobilizing leaders across industry, government, philanthropy, and finance to advance scalable solutions and strengthen the ecosystem needed to bring women’s health innovations to market and scale. In this role, Dr. Patterson focuses on unlocking key system barriers to growth, including investment gaps, regulatory and reimbursement pathways, and barriers to access and awareness, helping translate scientific advances into real-world impact at scale. Prior to joining the Milken Institute, Dr. Patterson served as a Portfolio Lead at the Advanced Research Projects Agency for Health (ARPA-H) within the Office of Commercialization. She led the agency’s first Sprint for Women’s Health, a $113 million initiative to catalyze innovation and accelerate the commercialization of high-impact technologies. She also directed the Small Business Program and Launchpad Accelerator, advancing transition pathways and product readiness across ARPA-H’s portfolio. Earlier in her career, Dr. Patterson held roles at the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH), where she advanced translational programs spanning therapeutics and diagnostics, including contributions to the Rapid Acceleration of Diagnostics (RADx) initiative. Dr. Patterson earned her Ph.D. in Neuroscience and completed her postdoctoral training within the NIH Intramural Research Program.

Amanda “Mandy” Pinheiro, PhD, is a co-founder of Evina Biosciences, a preclinical-stage women’s health therapeutics company developing non-hormonal treatments for uterine fibroids. Mandy leads Evina's drug discovery program and company operations. She has secured federal and private funding to advance research originating at Northwestern University toward new treatment options for women. She earned her PhD in Molecular Biology, Cell Biology & Biochemistry and MS in Human Physiology from Boston University, and her BS in Biomedical Engineering from The University of Akron.

Liz is Founder of G2G Consulting, which creates and implements government to growth (G2G) strategies for clients—securing $550 million since 2007. We advance health and high-tech innovation for businesses and nonprofits by accessing non-dilutive funding, shaping policies and regulations, and building relationships with key decision-makers. Liz founded the Women’s Health Advocates, which is in all 50 states and has organized the first-ever Women’s Health Capitol Hill Day on May 21, 2025, Breast Cancer Hill Day on July 16, 2025, Congressional Briefings, online forums, an advocacy letter-writing campaign, and legislative language for appropriations bills and amendments. Previously, she served as Legislative Director in Congress where she staffed the Congressional Caucus for Women’s Issues, Armed Services Committee and Small Business Committee and served as a Policy Analyst for UK Parliament’s Health Committee and as congressional and presidential campaign staff. She received the Woman Entrepreneur of the Year Award and Women of Achievement Award and earned her MPH from Harvard, JD from George Washington, and BA from Colgate.

Neda Razavi is CEO of iSono Health, where she's leading the shift of breast ultrasound from a specialist skill into something as ordinary as a blood pressure check—no sonographer required, no specialist suite. She backed the company early, as a seed investor, before it had FDA clearance; she took over as CEO because she believed the technology deserved a faster path to patients than the one it was on. Her path includes 26 years in medtech and diagnostics at Illumina, Roche, Abbott Laboratory, Medtronic, Natera, and Kythera (Allergan), Baxter BioScience (Takeda), where she's launched 65 products across seven platforms, work that touched areas from genomic sequencing to coagulation testing to Type II diabetes care. Trained as a cellular microbiologist with an MBA in finance and advance degree in Genetics and Genomics, she's spent her career at the point where hard science must become something a clinic can actually use. She's also a single mother of three, raising two daughters in a country where a third of women skip their breast screening entirely. That's not a footnote to her work—it's most of the reason for it. She wants her daughters to inherit a healthcare system where early detection isn't a privilege you have to know how to access.

Judy Regensteiner, PhD, is the Director of the Ludeman Family Center for Women’s Health Research and Distinguished Professor of Medicine in the Divisions of Internal Medicine and Cardiology at University of Colorado Anschutz. She holds the Judith & Joseph Wagner Chair in Women’s Health Research. Her research expertise is in the cardiovascular effects of diabetes with a specific focus on women with type 2. Her lab has been funded for over 30 years and she has authored more than 190 research publications. She is also known for her research on peripheral arterial disease. Dr. Regensteiner is currently PI for the National Institutes of Health’s Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) grant as well an NIH R01 grant. As co-founder and Director of the Ludeman Center, Dr. Regensteiner leads an interdisciplinary team of researchers who focus on women’s health and sex differences research.

Dr. Kathryn Rexrode is the Chief Academic Officer at Brigham and Women’s Hospital (BWH), Chief of the Division of Women’s Health in the Department of Medicine at Mass General Brigham, and a Professor of Medicine at Harvard Medical School. As Chief Academic Officer she supports and advances the research and educational missions of the hospital. Dr. Rexrode has broad and deep research experience in women’s health and is the author of more than 300 research publications. She is also Chief of the Division of Women’s Health and the Director of the Gretchen and Edward Fish Center for Women’s Health which provides comprehensive women’s health services, including 14 specialties and a dedicated clinic for menopause and midlife care. Building on its core mission of leading the field in state-of-the-art care for women, the Division of Women’s Health conducts translational women’s health research and leads innovative education programs for medical students, residents, and faculty to advance the health of women.

Cassie Ricci joined Roche Diagnostics in 2022 and currently leads the organization's Alliance Development Program within the Access & Government Affairs team. In her role, Cassie is responsible for establishing and growing relationships with patient advocacy and stakeholder organizations to advance the value of diagnostics and patient outcomes. In addition to leading Alliance, Cassie is a key contributor to Roche Diagnostics' federal legislative and public policy priorities. Prior to joining Roche Diagnostics, Cassie held roles at GE HealthCare and Deloitte and has over a decade of health policy expertise within the medical imaging and diagnostics industries.

Livia Robic is Product Manager for Women's Health at Withings, leading the company's strategy across fertility, pregnancy, perimenopause and menopause. With a background in bioengineering, she brings deep expertise in physiology and connected health technology to the intersection of data science and women's care. She drove the research behind the Menopause Transition 2026 Report and is passionate about closing the menopause care gap through preventive monitoring and personalized health insights.

Sarah Rose is Chief Operating Officer of Teal Health, where she uses more than 25 years of consumer product and general management experience to help women get essential preventive care. Before Teal, she was Chief Product Officer at Tinder and President and Chief Product Officer at TaskRabbit, where she drove significant year-over-year growth and led global expansion. She has also held leadership roles at Ipsy, BabyCenter, ModCloth and UrbanSitter, much of it focused on building experiences for women. The San Francisco Business Times named her one of its 50 Most Influential Women in Business. Sarah holds a bachelor’s degree from Duke University and an MBA from UC Berkeley’s Haas School of Business.

Eric Schaefer leads the Innovation Fund at March of Dimes as the Senior Director – Portfolio Strategy & Investment. In this role he leads a venture fund investing in a portfolio of promising startups focused on addressing key clinical issues in the areas of maternal and infant health. Prior to March of Dimes, Eric served as Vice President, Healthcare Innovation at Coplex, a startup studio focused on developing new healthcare ventures with corporate partners. Eric also worked at UnitedHealth Group R&D where he collaborated with subject matter experts and business leaders to develop innovative investment projects for UHG. Eric has deep experience with healthcare providers, having worked in strategy and business development roles for Allina Health and North Memorial Health. Eric has a BA from the University of Wisconsin, and an MBA from the University of Minnesota.

Rachel Braun Scherl is a marketing strategist, business builder, serial founder, author, speaker, podcast co-host, and Vagipreneur, focused on building businesses in women's health – defined as conditions that affect women solely, disproportionately, and differently. She brings deep knowledge of menstruation, fertility, sexual disease prevention, birth control, pregnancy, menopause, and incontinence to help brands and businesses grow. As President of Semprae Laboratories, Rachel and her team built a company that developed and marketed sexual health and wellness products for women - creating a new category and transforming women’s health. Semprae attracted significant media attention and industry interest and was sold to a specialty pharmaceutical company in 2013. Rachel has continued to work with companies in women’s health, both large and small, effectively driving topline growth. As an advisor and partner, she serves as the connective tissue between players in the ecosystem, creating strategic partnerships for funding, distribution, and marketing. She has authored many articles and a best-selling book, Orgasmic Leadership: Profiting from the Coming Surge in Women’s Sexual Health and Wellness. As the co-host of the podcast, Business of the V, Rachel drives the conversation about the intersection of unmet needs and unanswered questions in women’s health, with businesses being created to respond to them. Rachel is a frequent public speaker at universities, colleges, and industry conferences, including Duke, Stanford, CES, SXSW, Women’s Health Innovation Series, Johnson & Johnson, AbbVie, and the Minnesota Vikings, among others. She has completed hundreds of strategic growth projects for leading companies, including Allergan, Bayer, Church & Dwight, J&J, Merck, Pfizer, and Sanofi, among others as well as venture-backed start-ups. Rachel serves as a valued advisor, board member, and mentor to executives and founders. In addition to her client and advisory work, Rachel writes for ForbesWomen and has conducted and published primary research on women’s health entrepreneurship, company survival and growth. Rachel co-teaches a mini-MBA in Women’s Health, providing an overview of critical fundamentals, vocabulary, and complex issues that are critical to understand how to navigate the system. To date, nearly 350 participants have completed the program. Rachel is also an integral part of the founding team and serves as Head of Growth for 51&, which focuses on creating an infrastructure and business designed to helps women navigate the current system while rebuilding it for the future.

Dr. Aritro Sen is the Co-Founder and Chief Scientific Officer of Maipl Therapeutics, a biotechnology company developing first-in-class medicines for women’s health indications. Previously, Dr. Sen served as a Program Officer at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, where he oversaw programs across three branches: Fertility & Infertility, Gynecological Health & Disease, and Pregnancy & Perinatology. He was also the Director and Therapeutic Area Head for Reproductive Medicine & Maternal Health in Global Drug Discovery and External Innovation at Ferring Pharmaceuticals. Earlier in his career, he held faculty appointments at Michigan State University in the Reproductive and Developmental Sciences Program and at the University of Rochester Medical Center in the Division of Endocrinology & Metabolism, Department of Medicine. In addition, he has served as a consultant for the Center for Human Reproduction in New York, NY, and continues to serve as an expert advisor to several venture capital firms and pharmaceutical companies. Dr. Sen earned his Master’s in Biochemistry from the University of Calcutta, India, and a Ph.D. in Cell and Molecular Biology from West Virginia University. He completed two postdoctoral fellowships: one in Reproductive Biology at Michigan State University and another in Molecular Endocrinology at the University of Texas Southwestern Medical Center. He has authored more than 45 publications, served as an Editorial Board member, Associate Editor, and reviewer for multiple scientific journals, and participated on numerous federal, foundation, industry, and international grant review panels. Dr. Sen is also the recipient of the Pfizer Early Career Investigator Award from the Endocrine Society.

Dr. Shikanov is a Professor in the Department of Biomedical Engineering at the University of Michigan, home to the #7-ranked biomedical engineering program in the country. There, she also serves as the Associate Director of the Cellular and Molecular Biology Graduate program. Dr. Shikanov’s academic journey began with a Ph.D. in Medicinal Chemistry and Pharmaceutical Sciences from Hebrew University. She then pursued postdoctoral training in women's health at Northwestern University with Dr. Lonnie Shea and Dr. Teresa Woodruff, pioneers in reproductive science. Since starting her lab at the University of Michigan in 2012, she has established a research program focused on ovarian function, fertility preservation, and reproductive health. A major focus of her work is developing immuno-isolation devices for ovarian tissue transplantation, designed to restore ovarian endocrine function in young girls who have undergone chemotherapy and lost puberty signals or fertility. She has conducted preclinical studies in non-human primates to test these devices and is now advancing this work into human studies in collaboration with an IRB that facilitates the collection of reproductive tract tissues from deceased donors for follicle retrieval. Dr. Shikanov’s lab is also engineering biomimetic matrices to promote folliculogenesis, exploring in vitro maturation of early-stage follicles, and investigating the reproductive consequences of testosterone administration in transgender individuals. Her research is highly interdisciplinary, integrating biomaterials, reproductive biology, and regenerative medicine to address urgent clinical needs in women's health. Her contributions have been widely recognized, with support from multiple NIH R01 grants, the Chan Zuckerberg Initiative, an NSF CAREER Award, and the Cellular and Molecular Bioengineering (CMBE) Young Innovator Award. She is also a Fellow of the American Institute of Medical and Biological Engineering (AIMBE), reflecting her leadership and impact in the field.

Dr. Luba Soskin is a board-certified obstetrician-gynecologist and Global Clinical Lead in Women’s Healthcare at Bayer. She brings experience across clinical practice, academia, and pharmaceutical development, with a focus on advancing innovative solutions for women’s health. Her work spans clinical development and scientific strategy, complemented by advisory roles supporting innovation in the women’s-health ecosystem.

Raphaelle Taub, PhD, is the co-founder of Matricis.ai, a company developing artificial intelligence for gynecological imaging, with an initial focus on endometriosis. She holds a PhD in fundamental physics, with a background in biophysics, and previously worked in data science and early-stage deep technology ventures. Her work connects medical imaging, clinical evidence and entrepreneurship to improve how gynecological conditions are identified and understood. Based in New York, she works with radiologists, gynecologists and healthcare partners in Europe and the United States to translate imaging AI into clinical practice and build more accessible, coordinated diagnostic pathways for women with gynecological conditions.

Sarah Temkin, MD, FACS serves as Senior Director, Early Detection at the American Cancer Society. She previously served as the Associate Director for Clinical Research at the NIH Office of Research on Women's Health where she developed and disseminated research priorities on women's health for the agency. A gynecologic oncologist, Dr. Temkin has a recognized expertise in cancer and women, cancer prevention and early detection, and health equity.

Laura Yecies is the CEO of Osteoboost Health, Inc., the company behind the first and only FDA-cleared, non-drug wearable for low bone density. She has over 35 years of leadership experience in the technology and medical sectors. Before Osteoboost, Laura served as CEO of three venture-backed startups, SugarSync, acquired by J2 Global, Catch, which she successfully sold to Apple, and CEO of Neurosync and was recently named a Forbes 50 over 50. Previously, she held leadership positions at Netscape, Yahoo and Check Point. She holds an MBA from Harvard, an MS from Georgetown, and a BA from Dartmouth. She speaks four languages and lives in the Bay Area with her family.

Wendy Young, PhD, is a biotechnology, pharma, and life sciences executive and board advisor with more than 30 years of experience in the discovery and development of new medicines for patients. She currently serves as a board member and scientific advisor at several venture capital backed start-up companies and is an advisor at Google Ventures. Previously, Wendy was an executive partner at MPM Capital, where she actively supported investments and new company builds. Prior to this role, she was the Senior Vice President, Small Molecule Drug Discovery at Genentech, where for 15 years she actively built and led the research & discovery organization. Under her leadership, more than 25 clinical candidates progressed into development. Additionally, Wendy led the BTK discovery program and is co-inventor of fenebrutinib, which is currently in Phase 3 trials for multiple sclerosis. Prior to joining Genentech, Wendy held roles of increasing scientific leadership at Celera Genomics and Scios, a J&J company. Wendy is an inventor and/or author on more than 70 published patents and manuscripts. Wendy earned her PhD in chemistry from Princeton University under the guidance of E.C. Taylor and was an American Cancer Society Postdoctoral Fellow in the laboratories of Samuel Danishefsky at Sloan Kettering Cancer Center.

Elcin Zan, MD is the Chair of Nuclear Medicine at Cleveland Clinic. Elcin focuses on exploring the full potential of Radiopharmaceutical Therapies in oncology to meaningfully improve patient outcomes in clinic and research. Elcin and her team develop AGI tools to study the collective intelligence of cancer from cells to body-wide networks integrating pathology and PET diagnostics.